SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Tetsuhiro Chiba, Atsushi Iwama, Osamu Yokosuka, Cancer stem cells in hepatocellular carcinoma: Therapeutic implications based on stem cell biology, Hepatology Research, 2015, 45, 8
  2. 2
    Anders Wittrup, Judy Lieberman, Knocking down disease: a progress report on siRNA therapeutics, Nature Reviews Genetics, 2015, 16, 9, 543

    CrossRef

  3. 3
    Jordi Bruix, Kwang-Hyub Han, Gregory Gores, Josep Maria Llovet, Vincenzo Mazzaferro, Liver cancer: Approaching a personalized care, Journal of Hepatology, 2015, 62, 1, S144

    CrossRef

  4. 4
    Mazen Noureddin, Mary E. Rinella, Nonalcoholic Fatty Liver Disease, Diabetes, Obesity, and Hepatocellular Carcinoma, Clinics in Liver Disease, 2015, 19, 2, 361

    CrossRef

  5. 5
    Helena Cornella, Clara Alsinet, Sergi Sayols, Zhongyang Zhang, Ke Hao, Laia Cabellos, Yujin Hoshida, Augusto Villanueva, Swan Thung, Stephen C. Ward, Leonardo Rodriguez-Carunchio, Maria Vila-Casadesús, Sandrine Imbeaud, Anja Lachenmayer, Alberto Quaglia, David M. Nagorney, Beatriz Minguez, Flair Carrilho, Lewis R. Roberts, Samuel Waxman, Vincenzo Mazzaferro, Myron Schwartz, Manel Esteller, Nigel D. Heaton, Jessica Zucman-Rossi, Josep M. Llovet, Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma, Gastroenterology, 2015, 148, 4, 806

    CrossRef

  6. 6
    R. Buzzoni, S. Pusceddu, E. Bajetta, F. De Braud, M. Platania, C. Iannacone, M. Cantore, A. Mambrini, A. Bertolini, O. Alabiso, A. Ciarlo, C. Turco, V. Mazzaferro, Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study, Annals of Oncology, 2014, 25, 8, 1597

    CrossRef

  7. 7
    Atsushi Umemura, Eek Joong Park, Koji Taniguchi, Jun Hee Lee, Shabnam Shalapour, Mark A. Valasek, Mariam Aghajan, Hayato Nakagawa, Ekihiro Seki, Michael N. Hall, Michael Karin, Liver Damage, Inflammation, and Enhanced Tumorigenesis after Persistent mTORC1 Inhibition, Cell Metabolism, 2014, 20, 1, 133

    CrossRef

  8. 8
    Kan Chen, Kwan Man, Herold J. Metselaar, Harry L. A. Janssen, Maikel P. Peppelenbosch, Qiuwei Pan, Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation, Liver Transplantation, 2014, 20, 3
  9. 9
    Robert T. Abraham, Too Little mTORC1 Activity Injures the Liver, Cell Metabolism, 2014, 20, 1, 4

    CrossRef

  10. 10
    J.C. Nault, J. Zucman-Rossi, Pathobiology of Human Disease, 2014,

    CrossRef

  11. 11
    Akio Nakashima, Keiko Tanimura-Ito, Noriko Oshiro, Satoshi Eguchi, Takafumi Miyamoto, Ayaka Momonami, Shinji Kamada, Kazuyoshi Yonezawa, Ushio Kikkawa, A positive role of mammalian Tip41-like protein, TIPRL, in the amino-acid dependent mTORC1-signaling pathway through interaction with PP2A, FEBS Letters, 2013, 587, 18, 2924

    CrossRef

  12. 12
    Siddharth Singh, Preet Paul Singh, Hepatocellular cancer risk in diabetes: Not all diabetics are the same, Hepatology, 2013, 58, 6